Join to View Full Profile
3181 Sw Sam Jackson Park RdPortland, OR 97239
Phone+1 503-494-5058
Dr. Meyers is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Utah HealthFellowship, Hematology and Medical Oncology, 2001 - 2004
Oregon Health & Science University (OHSU Health)Residency, Internal Medicine, 1998 - 2001
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1998
Certifications & Licensure
OR State Medical License 1999 - 2027
WA State Medical License 2022 - 2027
UT State Medical License 2001 - 2006
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Geriatric Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2012, 2014-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301) Start of enrollment: 2006 Jan 01
- Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801) Start of enrollment: 2010 Apr 01
- Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901) Start of enrollment: 2011 Jun 01
Publications & Presentations
PubMed
- Attenuation of Immune Senescence Markers After Intensive Cancer Therapy Through Resistance Training: A Pilot Study.Laura F Newell, Eric Twohey, Jason Sweetnam, Sasha Skendzel, John Stingle
Cancers. 2026-05-24 - Results of a phase 1 trial testing ruxolitinib plus venetoclax in patients with relapsed/refractory acute myeloid leukemia.Uma Borate, Cristina E Tognon, Yazan F Madanat, Shikha Misra, Andy Kaempf
Blood Neoplasia. 2026-05-01 - Real-World Clinical Outcomes in Melanoma Patients Treated at a Single-Center Tumor Infiltrating Lymphocyte (TIL) Therapy Program Using Commercial Lifileucel.Amrita Desai, Cristian D Valenzuela, Kevin Christmas, Denise Lackey, Jacqueline Trussell
Transplantation and Cellular Therapy. 2026-04-25
Abstracts/Posters
- Equate, a Phase 1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of a Novel Targeted Anti-CD6 Therapy, Itolizu...Gabrielle Meyers, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Retrospect Reviews of PNH Tests with Long-Term Follow-up in a Single InstitutionGabrielle Meyers, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Press Mentions
Research Offers Clues for Potential Widespread HIV Cure in People: New Study Reveals First Details on How Stem Cell Transplantation Can Kill Virus That Causes AIDSMay 25th, 2023- New Study Reveals First Details on How Stem Cell Transplant Can Kill Viruses That Cause AIDS – ScienceDailyJune 3rd, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
